BriaCell Therapeutics’ Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated Patients
BriaCell Therapeutics Corp (NASDAQ: BCTX) reported preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell's Bria-IMT regimen: patients that have developed resistance to (and failed to respond to)